Skip to content

    CORONA Remedies Q1 FY27 earnings call

    CORONA
    Healthcare·3 Aug 2026
    Management Summary

    CORONA Remedies Limited reported a strong Q1 FY27, with revenue growing 21.9% year-on-year to INR422 crores, significantly exceeding its 15% guidance. The India business led this growth, expanding 22.7% and outperforming the Indian Pharmaceutical Market. Profitability also saw robust improvement, with EBITDA growing 33.5% and PAT increasing 30.1%, driven by favorable product mix and operating leverage. The company also successfully commercialized its new Europe-GMP approved hormone manufacturing facility and integrated the Wokadine acquisition.

    Highlights

    5

    • Revenue for Q1 FY27 stood at INR422 crores, reflecting a healthy growth of 21.9% Y-o-Y, surpassing the stated growth guidance of 15%.

    • India business delivered an impressive 22.7% year-on-year revenue growth in Q1 FY27, significantly outperforming the Indian Pharmaceutical Market which grew by 11.6%.

    • EBITDA stood at INR93 crores, a growth of 33.5% Y-o-Y, with EBITDA margin improving by around 190 bps and standing at 22%.

    • Profit after tax stood at INR60 crores, a growth of 30.1% Y-o-Y, with PAT margins increasing by 90 bps to 14.2%.

    • Successfully commercialized India's most advanced Europe-GMP approved Women's hormone manufacturing facility and renewed EU-GMP certification for Ahmedabad oral solid dosage form facility.

    Concerns

    2

    • Potential 100 basis point hit on gross margins in Q2 FY27 due to geopolitical raw material price disturbance.

    • The new hormonal facility's asset turnover is expected to be less than one in FY27, with a gradual ramp-up to two to three times over the next three years.

    Key financials

    Single quarter

    08 metrics
    1. 01Revenue₹422 Cr+21.9%YoY
    2. 02Revenue (ex-Wokadine)—+21.4%YoY
    3. 03India Business Revenue Growth—+22.7%YoY
    4. 04EBITDA₹93 Cr+33.5%YoY
    5. 05EBITDA Margin22%

    Segment breakdown

    Women's Healthcare
    23.3% Revenue Growth9.4% IPM Growth
    Urology
    27.6% Revenue Growth14.9% IPM Growth
    Cardio-Diabeto
    1.7x Market Outperformance
    Pain Management
    1.4x Market Outperformance
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    M&A

    Wokadine

    acquisition · integrated · Consideration ₹NaN (undisclosed)

    M&A

    Bayer brand (Noklot)

    acquisition · integrated · Consideration ₹NaN (undisclosed)

    Guidance & targets

    12
    CategoryTargetPriority
    Revenue
    FY27 Organic Revenue Growth
    15%
    		High
    Revenue
    FY27 Inorganic Revenue Growth
    1.5% to 2%
    		High
    Revenue
    Inorganic Growth from Opportunities
    25%
    		High
    Profitability
    FY27 PAT Growth
    20%
    		High
    Headcount
    Medical Representative Addition
    6% to 8% (200 to 250 MRs)
    		High
    Product Growth
    Wokadine Brand Growth
    25% growth for INR20 crores to INR40 crores
    		High
    Asset Turnover
    Hormonal Plant Asset Turnover Ratio
    less than one in FY27, gradually two to three in next three years
    		High
    International Business
    Hormonal Plant Export Business Commencement
    12 to 18 months after dossier approval (by Nov/Dec 2026)
    		High
    International Business
    International Business Growth
    higher single digit
    		Medium
    Business Mix
    India Business Share
    >90%
    		High
    Manufacturing
    In-house vs Outsourced Mix
    60-40
    		High
    Market Share
    Semaglutide Market Position
    top 10
    		Medium

    What to watch in Q2 FY27

    5

    Raw Material Price Impact on Margins

    Next quarter (Q2 FY27 results)
    CurrentQ1 FY27 unaffected due to stock; 100 bps hit anticipated for Q2 FY27.
    TargetActual margin impact in Q2 FY27.

    Why it matters

    This directly impacts profitability and management's ability to mitigate external shocks from geopolitical events.

    But the answer is yes, 100 basis point here and there we may get the hit and that's why we are trying to reduce other operating things and try to maintain the guidance which we have been told about 20% PAT growth.

    Risks & concerns

    2
    RiskSeverity

    Raw Material Price Volatility

    Geopolitical disturbance started in February 2026, potentially leading to a 100 bps hit on gross margins in Q2 FY27 due to new stock procurement. — Management acknowledged

    medium

    New Hormonal Plant Ramp-up Period

    The new EU-GMP hormonal facility, commercialized on June 30, 2026, is expected to have an asset turnover ratio of less than one in FY27, requiring 2-3 years to reach full potential (2-3x turnover). — Management acknowledged

    low

    Q&A highlights

    8

    “If you look at this Indian Pharmaceutical Market since last 20, 25 years, this has always been performed in the tune of lower single-digit and that has again come in the force after few years of COVID, post-COVID and post-post-COVID. So, I think so now it is sustainable, according to me this industry growth will continue to grow in the tune of around 10%, 9% to 11% in between.”

    Management confirms that the observed double-digit IPM growth is sustainable in the lower range (9-11%) post-COVID, providing clarity on market conditions.

    asked by Pratik Dharmshi

    3 min read8 chapters

    Detailed Narrative

    01

    Strong Q1 FY27 Financial Performance

    CORONA Remedies Limited delivered a robust Q1 FY27, with revenue growing 21.9% year-on-year to INR422 crores, surpassing its stated growth guidance of 15%. The India business was a key driver, achieving an impressive 22.7% year-on-year revenue growth, significantly outperforming the Indian Pharmaceutical Market's 11.6% growth during the same period. This performance reflects strong demand and effective market execution, contributing to growth at nearly twice the pace of the IPM.

    02

    Significant Profitability Expansion

    Profitability saw substantial improvement in Q1 FY27, with EBITDA increasing by 33.5% year-on-year to INR93 crores. The EBITDA margin expanded by approximately 190 basis points, reaching 22%. Similarly, Profit After Tax (PAT) grew 30.1% year-on-year to INR60 crores, and the PAT margin improved by 90 basis points to 14.2%. This margin expansion was attributed to a favorable product mix and operational efficiencies, despite management's caution regarding potential raw material price volatility in the upcoming quarter.

    03

    Therapeutic Area Leadership and Growth Drivers

    The company maintains strong leadership positions across its four key therapeutic areas, ranking 5th in Women's Healthcare and Pain Management, 9th in Urology, and 20th in the Cardio-Diabeto segment. Women's Healthcare revenue grew by 23.3%, nearly 2.5 times the IPM growth of 9.4%, while Urology grew 27.6% compared to the IPM's 14.9%. The chronic and semi-chronic therapies now constitute a significant 73.4% of the total portfolio, underscoring the success of its engine brand strategy, with two brands exceeding INR100 crores and over 40 brands exceeding INR10 crores in annual revenues (MAT June 2026).

    04

    New EU-GMP Hormonal Manufacturing Facility

    CORONA successfully commercialized India's most advanced Europe-GMP approved Women's hormone manufacturing facility on June 30, 2026, following a capital investment of INR130 crores. This state-of-the-art facility is designed to produce complex hormonal products, enhancing manufacturing flexibility and operational efficiency. While currently serving the domestic market, the company is in the final stages of preparing dossiers for international markets, with approvals expected in 12-18 months and significant export business anticipated by FY29.

    05

    Strategic Acquisitions and Integration Progress

    The company successfully integrated Wokadine, acquired at the end of FY26 for INR97 crores plus GST, into its brand-building strategy, targeting 25% growth over the next three years to double its revenue contribution from INR20 crores to INR40 crores. Additionally, the acquisition of a Bayer brand for INR7 crores, including the Noklot brand in the cardio-metabolic segment, saw its acquisition cost recovered in Q1 FY27. These integrations are expected to drive sales acceleration and growth in the coming quarters⏳.

    06

    Capital Allocation and Future Outlook

    CORONA reiterated its FY27 guidance of 15% organic revenue growth and 20% PAT growth, with an additional 1.5-2% inorganic revenue growth. The company plans to continue expanding its medical representative force by 6-8% annually, translating to 200-250 new MRs each year. The new hormonal plant's asset turnover is projected to be less than one in FY27, gradually increasing to 2-3 times over the subsequent three years, with India remaining the core market, accounting for over 90% of the business.

    07

    Employee Costs and Operating Leverage

    The company's employee costs are currently higher compared to peers, primarily due to the strategic addition of 1,000 medical representatives over the last three and a half years, bringing the total to 3,111. Management expects that as the productivity per medical representative increases, operating leverage will come into play, leading to an improvement in these costs over time⏳. Sales promotion expenses, being variable and linked to revenue, are also managed to ensure efficiency and contribute to operating leverage.

    08

    API Backward Integration and Quality Assurance

    CORONA holds a 31% stake in La Chandra Pharma Lab, which serves as a crucial backward integration for the production of quality hormonal APIs, including progesterone and norethisterone. La Chandra's EU-GMP and US DMF approvals ensure high-quality API supply. The company currently sources 60-65% of its API consumption from La Chandra, leveraging this strategic partnership to ensure a reliable and high-quality supply chain for its hormonal products.

    This is an AI-generated summary of a publicly available earnings call transcript.